These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34402193)

  • 1. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
    Wu S; Wang Y
    Altern Ther Health Med; 2024 Jul; 30(7):268-273. PubMed ID: 37971460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
    Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
    Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
    Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
    Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
    Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
    Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nesprin1 Deficiency Is Associated with Poor Prognosis of Renal Cell Carcinoma and Resistance to Sunitinib Treatment.
    Fukushima T; Kobatake K; Miura K; Takemoto K; Yamanaka R; Tasaka R; Kohada Y; Miyamoto S; Sekino Y; Kitano H; Goto K; Ikeda K; Goriki A; Hieda K; Kaminuma O; Hinata N
    Oncology; 2024; 102(10):868-879. PubMed ID: 38442705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization.
    Zheng X; Wang Y; Qiu X
    Eur J Pharmacol; 2024 Oct; 980():176840. PubMed ID: 39038636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
    Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
    Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.
    Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J
    Br J Cancer; 2024 Jul; 131(2):347-360. PubMed ID: 38822145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underlying mechanisms of novel cuproptosis-related dihydrolipoamide branched-chain transacylase E2 (DBT) signature in sunitinib-resistant clear-cell renal cell carcinoma.
    Lai SW; Weng PW; Yadav VK; Pikatan NW; Yeh CT; Hsieh MS; Chou CL
    Aging (Albany NY); 2024 Feb; 16(3):2679-2701. PubMed ID: 38305803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
    Rausch M; Rutz A; Allard PM; Delucinge-Vivier C; Docquier M; Dormond O; Wolfender JL; Nowak-Sliwinska P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop.
    Jiang Z; Yang G; Wang G; Wan J; Zhang Y; Song W; Zhang H; Ni J; Zhang H; Luo M; Wang K; Peng B
    J Exp Clin Cancer Res; 2024 Oct; 43(1):288. PubMed ID: 39425205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome
    Jiang A; Meng J; Gong W; Zhang Z; Gan X; Wang J; Wu Z; Liu B; Qu L; Wang L
    Front Immunol; 2022; 13():842069. PubMed ID: 35281041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients.
    Armesto M; Nemours S; Arestín M; Bernal I; Solano-Iturri JD; Manrique M; Basterretxea L; Larrinaga G; Angulo JC; Lecumberri D; Iturregui AM; López JI; Lawrie CH
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
    Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
    BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.